This subsequent closing follows a Special Meeting of Stockholders held on March 2, 2016, whereby over a majority of the Company’s outstanding shares of common stock were represented by a valid proxy with over eighty percent of the voted shares in favor of the issuance. Apricus plans to use the net proceeds of the offering to fund working capital and general corporate purposes, including to advance its clinical development pipeline.